Alitair Announces Issuance of Patent Covering its
Prescription Drug Overdose Reduction Technology, ODR™
MORRISTOWN, New Jersey – January 8, 2016 – Alitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on respiratory health, today announced the issuance of U.S. Patent No. 9,211,292, covering its prescription drug overdose reduction technology, ODR™ .
Alitair Pharmaceuticals, Inc. Selected to Present at Cavendish Global Health Impact Forum
Forum brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences
MORRISTOWN, New Jersey – October 26, 2015 – Alitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company with multiple respiratory product candidates in development, announced today that it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by the Cleveland Clinic in Cleveland, Ohio, October 25 - 28, 2015.
Alitair Receives a U.S. Composition of Matter Patent for Benzonatate Polacrilex
MORRISTOWN, New Jersey – September 4, 2014 – Alitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company with multiple respiratory product candidates in development, today announced that it has received a second patent from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of
Alitair Announces Issuance of an Additional Patent Covering its Platform Drug Delivery Technology, REA™
MORRISTOWN, New Jersey – January 21, 2014 – Alitair Pharmaceuticals, Inc., a revenue-stage pharmaceutical company with multiple respiratory product candidates in development, today announced the issuance of U.S. Patent No. 8,617,602 from the United States Patent and Trademark Office (USPTO) for its ion exchange resin drug delivery technology, REA™.
Alitair Receives Orphan Drug Designation for Erdosteine® in Bronchiectasis
Alitair to Seek U.S. Approval for Erdosteine, Already Approved in 50 Countries
MORRISTOWN, New Jersey – January 7, 2014 – Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidate, Erdosteine®, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.
Alitair Pharmaceuticals and Edmond Pharma Announce Erdosteine® Licensing Agreement
Alitair to Seek U.S. Approval for Erdosteine, Already Approved in 43 Countries
MORRISTOWN, New Jersey and MILAN – September 25, 2013 – Alitair Pharmaceuticals, Inc., and Edmond Pharma S.r.l. today announced that they have entered into a definitive agreement for Alitair Pharmaceuticals to license Erdosteine, a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties, from Edmond Pharma for development as an orphan drug in the United States and Canada. Financial terms of
Alitair Files Orphan Drug Designation to Treat Bronchiectasis with ALT-07
Orphan Drug Designation Could Provide Financial Incentives and Faster Regulatory Review
MORRISTOWN, New Jersey – May 7, 2013 – Alitair Pharmaceuticals, Inc. today announced that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for ALT-07, an oral bronchodilator and anti-inflammatory compound, for use in the treatment of bronchiectasis, a respiratory disease that
Alitair Announces Issuance of Patent Covering its Safer Formulation of Benzonatate
MORRISTOWN, New Jersey – January 24, 2013 – Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company focused on respiratory health, today announced the issuance of U.S. Patent No. 8,357,398. This is the second patent issued to the Company for its groundbreaking ion exchange resin drug delivery technology, REA™. This newest patent covers Alitair’s ion exchange resin formulation of benzonatate and
Alitair Announces Notice of Patent Allowance for Safer Formulation of Benzonatate
MORRISTOWN, New Jersey – September 26, 2012 – Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate. The patent includes specific claims for reducing or eliminating the choking hazard associated with
Alitair Announces Issuance of Patent Covering its Platform Drug Delivery Technology, REA™
MORRISTOWN, New Jersey – May 29, 2012 – Alitair Pharmaceuticals, Inc., a mid-stage pharmaceutical company with multiple respiratory product candidates in development, today announced the issuance of U.S. Patent No. 8,187,617 from the United States Patent and Trademark Office (USPTO) for
Alitair Announces Notice of Patent Allowance for its Platform Drug Delivery Technology, REA™
MORRISTOWN, New Jersey – April 12, 2012 – Alitair Pharmaceuticals, Inc., a mid-stage pharmaceutical company with multiple respiratory product candidates in development, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its
The Cough Company Is Now Alitair Pharmaceuticals, Inc.
MORRISTOWN, New Jersey – December 15, 2011 – Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple therapeutic candidates in development, today announced that The Cough Company is now doing business under the Alitair name. Information about Alitair’s prescription cough product strategy can be found on
Alitair Pharmaceuticals Announces Filing of Patent for Prescription Drug Overdose Reduction Technology
MORRISTOWN, New Jersey – Jan. 10, 2011 – Alitair Pharmaceuticals, Inc., a life sciences product development company, today announced that it has filed a patent application with the United States Patent & Trademark Office. The patent claims compositions and
The Cough Company Announces Partnership to Develop Prescription Cough Products
MORRISTOWN, New Jersey – August 9, 2010 – The Cough Company, a life sciences product development company focused on improving therapies for cough, pain, and women’s health today announced the closing of a product development deal with
The Cough Company Announces a New Over-the-Counter 12-Hour DM Formulation
MORRISTOWN, New Jersey – Jan. 26, 2010 – The Cough Company, a life sciences product development company focused on improving therapies for cough, today announced the successful completion of proof of concept for its
Alitair Pharmaceuticals Wins Federal Grant to Research Technology Aimed at Reducing Prescription Drug Overdose Deaths
MORRISTOWN, New Jersey – Nov. 1, 2010 – Alitair Pharmaceuticals, Inc., a life sciences product development company, today announced that it has been awarded a grant under the Qualifying Therapeutic Discovery Program (QTDP). The QTDP was part of the Health Care Reform Act and provides $1 billion in funding for
Top